Table 3.

Characteristics of Patient PBMCs Analyzed Approximately 1 Month After Adoptive Transfer

Patient No.	% of CD3		NY-ESO-1 Tetramer		Vβ13.1		Target (IFN-γ ELISPOTs/105 PBMCs)
	CD8	CD4	% of CD8	% of CD4	% of CD8	% of CD4	Tumor Cell*	Peptide†
Melanoma
1	91	9	13	14	48	43	120	1,220
2	61	39	60	38	85	63	2,380	15,000
3	76	24	2	< 1	32	5	23	84
4	93	7	3	< 1	23	29	35	1,440
5	70	28	11	< 1	20	4	130	2,250
6	94	6	< 1	< 1	4	5	1	33
7	71	27	18	7	38	11	400	3,050
8	66	32	11	19	30	53	840	6,270
9	41	50	39	26	76	44	540	5,280
10	65	31	< 1	< 1	3	10	1	15
11	69	28	12	7	42	29	210	2,450
Synovial cell sarcoma
12	28	50	32	45	50	59	125	1,750
13	42	53	7	6	12	13	130	1,840
14	76	23	38	24	71	56	6,600	13,400
15	69	26	6	12	26	42	274	2,780
16	68	28	7	4	24	18	570	1,480
17	57	39	< 1	< 1	7	3	0	1

Abbreviations: PBMCs, peripheral-blood mononuclear cells; IFN-γ, interferon gamma; ELISPOTs, enzyme-linked immunosorbent spots.

^*The HLA-A*0201–positive NY-ESO-1–positive cell line 624 mel was used to evaluate tumor-specific ELISPOT responses. Less than 10 ELISPOTs/10⁵ PBMCs were observed in response to the HLA-A*0201–positive NY-ESO-1–negative tumor cell line 526 mel with the exception of patients 7, 14, and 15, for whom 41, 40, and 27 ELISPOTs/10⁵ PBMCs were detected, respectively.

^†The response against the unpulsed C1RA2 target cells was subtracted from the response against the NY-ESO-1 peptide. Pretreatment ELISPOT responses to the NY-ESO-1 peptide were less than 10 ELISPOTs/10⁵ PBMCs with the exception of patient 3, whose PBMCs contained 55 ELISPOTs/10⁵ PBMCs.